WASHINGTON (dpa-AFX) - ArQule Inc. (ARQL) a clinical-stage biotechnology company Monday said it has regained worldwide rights to develop compounds covered under its AKT collaboration with Daiichi Sankyo Co., Ltd., including the lead compound emerging from this collaboration, ARQ 092. The company exects to present data from an ongoing Phase 1 trial with ARQ 092 at the American Association for Cancer Research Annual Meeting on April 9.
Commenting on the development, Brian Schwartz, chief medical officer of ArQule said, 'Regaining worldwide rights to the AKT program, including the novel oral agent, ARQ 092, adds significant value for ArQule, as it expands our proprietary pipeline in an exciting area of therapeutic development...AKT, also known as the serine/threonine kinase PKB, is believed to mediate a number of signal transduction processes and represents a potential therapeutic target for several cancers and other diseases.'
ARQ 092 is a selective AKT inhibitor that was discovered through technology from the ArQule Kinase Inhibitor Platform and optimized through a structure-based drug design methodology.
Copyright(c) 2013 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2013 AFX News
